Inhibitory Effect of 1‐β‐d‐Arabinofuranosylcytosine on the Synthesis of Phosphatidyl‐dCMP

The synthesis of phosphatidyl‐dCMP in mouse thymocytes is inhibited by the antineoplastic agent 1‐β‐d‐arabinofuranosyl cytosine (AraCyt)50% inhibition (ID50) being reached at an AraCyt concentration of 0.18 mM. IN the same cells, ID50 for DNA synthesis is 0.03 mM. This inhibition is probably mediate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: IUJVIDIN, S., FELEDI, C., MEDRANO, E.E., MORDOH, J.
Formato: JOUR
Materias:
cytarabine
deoxyribonuclease
radioisotope
cancer chemotherapy
drug inhibition
in vitro study
mouse
nonhuman
phosphatidyldeoxycytidine phosphate
therapy
thymocyte
thymus
Animal
Cytarabine
Deoxycytidine Monophosphate
Deoxycytosine Nucleotides
In Vitro
Mice
Mice, Inbred BALB C
Support, Non-U.S. Gov't
Thymus Gland
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_00142956_v130_n2_p293_IUJVIDIN
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires
Descripción
Sumario:The synthesis of phosphatidyl‐dCMP in mouse thymocytes is inhibited by the antineoplastic agent 1‐β‐d‐arabinofuranosyl cytosine (AraCyt)50% inhibition (ID50) being reached at an AraCyt concentration of 0.18 mM. IN the same cells, ID50 for DNA synthesis is 0.03 mM. This inhibition is probably mediated by the phosphorylated derivative of AraCyt (aCTP) since the synthesis of phosphatidyl‐dCMP from dCTP using permeabilized thymocytes is inhibited by a aCTP (ID50= 0.11 mM). The incorporatioin of [3H]AraCyt inbto the organic phase could also be detected, suggesting that this drug may act as a substrate for the enzyme that catalyzes the transfer of dCTP into phosphatidic acid. Copyright © 1983, Wiley Blackwell. All rights reserved

Ejemplares similares